MassMutual Private Wealth & Trust FSB Increases Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

MassMutual Private Wealth & Trust FSB boosted its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 1.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 21,076 shares of the medical research company’s stock after purchasing an additional 256 shares during the period. MassMutual Private Wealth & Trust FSB’s holdings in Edwards Lifesciences were worth $1,560,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in the company. Wellington Management Group LLP increased its holdings in Edwards Lifesciences by 86.3% in the 3rd quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock worth $2,080,845,000 after buying an additional 14,610,123 shares during the period. Assenagon Asset Management S.A. increased its holdings in Edwards Lifesciences by 475.8% in the fourth quarter. Assenagon Asset Management S.A. now owns 4,243,976 shares of the medical research company’s stock valued at $314,182,000 after buying an additional 3,506,886 shares in the last quarter. Jacobs Levy Equity Management Inc. increased its stake in shares of Edwards Lifesciences by 239.9% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 3,693,663 shares of the medical research company’s stock valued at $243,745,000 after purchasing an additional 2,606,950 shares in the last quarter. Seilern Investment Management Ltd purchased a new stake in shares of Edwards Lifesciences in the fourth quarter valued at approximately $109,490,000. Finally, Nordea Investment Management AB increased its holdings in Edwards Lifesciences by 34.6% in the 4th quarter. Nordea Investment Management AB now owns 4,057,013 shares of the medical research company’s stock worth $301,355,000 after acquiring an additional 1,043,484 shares in the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total value of $327,850.00. Following the transaction, the vice president now directly owns 46,936 shares of the company’s stock, valued at $3,077,593.52. The trade was a 9.63 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Daniel J. Lippis sold 2,500 shares of Edwards Lifesciences stock in a transaction on Monday, December 16th. The shares were sold at an average price of $74.08, for a total transaction of $185,200.00. Following the completion of the transaction, the vice president now owns 23,189 shares in the company, valued at approximately $1,717,841.12. This represents a 9.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 33,000 shares of company stock valued at $2,195,180 in the last ninety days. Insiders own 1.27% of the company’s stock.

Edwards Lifesciences Trading Down 0.1 %

Shares of EW stock opened at $69.77 on Tuesday. The company has a 50 day moving average price of $72.06 and a 200 day moving average price of $71.18. The stock has a market capitalization of $41.15 billion, a P/E ratio of 10.07, a price-to-earnings-growth ratio of 3.77 and a beta of 1.11. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $96.12.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The business had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.57 billion. During the same period in the previous year, the company posted $0.59 earnings per share. The business’s revenue for the quarter was up 8.9% on a year-over-year basis. Equities research analysts predict that Edwards Lifesciences Co. will post 2.56 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on EW. Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating and increased their target price for the company from $82.00 to $90.00 in a report on Monday, December 16th. Morgan Stanley reissued an “equal weight” rating and issued a $70.00 target price on shares of Edwards Lifesciences in a research note on Friday, October 11th. Truist Financial reiterated a “hold” rating and set a $78.00 price objective (up previously from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. Barclays raised their target price on Edwards Lifesciences from $85.00 to $88.00 and gave the stock an “overweight” rating in a research note on Monday, December 2nd. Finally, Sanford C. Bernstein raised shares of Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research report on Monday, October 28th. One analyst has rated the stock with a sell rating, fifteen have issued a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $78.48.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.